Page 1

RNS Number : 2917R Oxford Nanopore Technologies plc 19 August 2026 19 August 2026 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION Oxford Nanopore Technologies plc Interim results for the six months ended 30 June 2026 Strong margin and EBITDA performance supports progress towards breakeven in FY27 Oxford Nanopore Technologies plc ( LSE : ONT ) ( " Oxford Nanopore " or the " Group " ) , the company behind a new generation of molecular sensing technology based on nanopores , today announces its interim results for the six months ended 30 June 2026 . Francis Van Parys , Chief Executive Officer of Oxford Nanopore , commented : " Since joining the business , I have spent time listening to colleagues across the organisation and engaging with customers , partners and broader stakeholders . Together , we have refined our view of where our differentiated technology can create the greatest value . We are now translating that into a focused operational roadmap across four strategic priorities which will accelerate growth by concentrating our people , investment and innovation on a select group of high - potential applications across BioPharma , Clinical and Research end - markets . " We delivered encouraging results across these end - markets during the period , alongside continued progress in product development , operational performance and readiness for regulated markets . We also delivered strong financial progress , with gross margin increasing by 400 basis points to 62.2 % and the adjusted EBITDA loss more than halving year - on - year to £ 22.1 million . These results demonstrate the impact of improving gross profit and disciplined cost control and show that we are tracking well towards adjusted EBITDA breakeven in FY27 . " Our next chapter is about harnessing the collective strength of Oxford Nanopore to deploy our differentiated technology seamlessly and at scale across an ever - expanding customer base . Our focus is clear : to accelerate adoption in our fastest- growing end markets and realise our longer - term ambition to build Oxford Nanopore into a $ 1 billion - and - growing annual revenue business , delivering significant and sustainable value for all stakeholders . " Summary financial performance [ 1 ] £ million Unless otherwise stated Revenue Gross profit Gross margin Adjusted EBITDA [ 3 ] Loss for the period H1 H1 2026 2025 Change reported Change CC [ 2 ] 116.7 105.6 10.5 % 12.3 % 72.6 61.4 18.2 % 62.2 % 58.2 % + 400bps ( 22.1 ) ( 48.3 ) + £ 26.2m ( 48.0 ) ( 71.8 ) + £ 23.8m H1 Financial highlights Group revenue was £ 116.7 million , which grew by 12.3 % on a constant currency basis ( CC ) , and 10.5 % on a reported basis driven by strong adoption in EMEAI and across Applied end - markets offset by headwinds as previously disclosed in the H1 trading update . Regional performance was underpinned by strong growth in EMEAI and AMR , up by 23.8 % CC and 12.5 % CC respectively year - on - year . This was partly offset by an 8.4 % reduction in APAC , which reflected a 15.7 % decline in China . Growth was broad - based across customer end markets ; with Clinical revenue increasing 35.4 % , BioPharma 25.0 % , Industrial 6.2 % and Research 5.4 % . Revenue performance was led by the PromethION product range driven by strong demand for P2i . The MinION product range services and other devices , grew by 7.4 % . [ 4 ] , which increased by 15.7 % year - on - year and increased by 4.3 % and Other revenue , comprising kits , Gross margin increased by 400bps to 62.2 % ( H1 2025 : 58.2 % ) . The improvement reflected yield improvements across Flow Cells , scale and increased adoption of the new pricing model , together contributing to 305bps of underlying improvement . This was supplemented by the non - recurrence of the £ 3.3 million non - cash inventory charge recognised in H1 2025 ( + 315bps ) , partly offset by adverse product mix ( -160bps ) and foreign exchange movements ( -60bps ) . Adjusted EBITDA improved year - on - year and sequentially to £ ( 22.1 ) million , compared with £ ( 48.3 ) million in H1 2025 and £ ( 38.4 ) million in H2 2025 , reflecting continued progress towards profitability . The improvement was driven by gross profit growth and disciplined control of the cost base , with adjusted operating costs down 6.9 % year - on - year and down 9.6 % versus H2 2025 .